Early Phase Trial Shows PB2452 Immediately Reverses Ticagrelor’s Antiplatelet Activity
The monoclonal antibody fragment PB2452 effectively and immediately reversed the antiplatelet effects of ticagrelor in healthy volunteers, according to results from a phase I...
Adolescent and Young Adult Cancer Survivors Face Higher Risk of Second Cancers
People who were diagnosed with cancer as adolescents or young adults (AYAs) have an excess risk of developing a subsequent primary neoplasm later in...
Patient With HIV and Hodgkin Lymphoma Is Virus-Free Following Transplant
An allogeneic hematopoietic cell transplantation (alloHCT) intended to cure a patient’s refractory Hodgkin lymphoma (HL) may have also put his HIV virus into remission,...
JULIET Analysis Finds Durable Responses With Tisagenlecleucel in DLBCL
Half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded to tisagenlecleucel, and approximately two-thirds of responders are expected to remain...
Prognostic Impact of TP53 Mutations Varies in Patients With Complex Karyotype MDS
In an analysis of mutation data from patients with complex karyotype myelodysplastic syndromes (CK-MDS), the presence of TP53 mutations conferred a poor prognosis, but...
ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
Results from the phase II ELOQUENT-3 trial demonstrate that the combination of elotuzumab plus pomalidomide and dexamethasone extended progression-free survival (PFS) compared with pomalidomide...
Lenalidomide Maintenance Extends Survival Over Observation Alone in Newly Diagnosed Myeloma
New results from the large phase III Myeloma XI trial confirm that maintenance therapy with lenalidomide improves progressionfree survival (PFS) over observation alone in...
BCMA-Targeting Antibody Associated With Clinical Activity in Previously Treated Myeloma
In a first-in-human trial published in Lancet Oncology, the anti–B-cell maturation antigen (BCMA) antibody GSK2857916 was associated with clinical activity and was reasonably well...
Study of Single-Agent Nivolumab in Patients With Relapsed/Refractory DLBCL Fails to Meet Endpoint
Treatment with single-agent nivolumab was associated with “disappointingly low” response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to...
Combination of Ibrutinib and Nivolumab Appears Similar to Single-Agent Therapy in Early-Phase Trial
According to results from a phase I/II trial published in Lancet Haematology, treatment with a combination of ibrutinib and the checkpoint inhibitor nivolumab was...
Current Issue
May 2019, Volume 5, Issue 6
This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.
